A statement released earlier today by HC Wainwright about Aerie Pharmaceuticals Inc (NASDAQ:AERI) bumps the target price to $66.00
- Updated: September 20, 2016
HC Wainwright upped the estimated target of Aerie Pharmaceuticals Inc (NASDAQ:AERI) to $66, indicating a possible upside of 0.94%.
Previously on 9/15/2016, Cantor Fitzgerald reported about Aerie Pharmaceuticals Inc(NASDAQ:AERI) upped the target price from $44.00 to $50.00. At the time, this indicated a possible upside of 1.37%.
Showing a price of $33.97, Aerie Pharmaceuticals Inc (NASDAQ:AERI) traded 2.15% lower on the day. With the last stock price close up 101.34% from the two hundred day moving average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same period. AERI has logged a 50-day moving average of $20.33 and two hundred day average of $16.95. Trade volume was was up over the average, with 2,543,849 shares of AERI changing hands over the typical 874,639 shares.
Recent Performance Graphic:
With a market capitalization of $0.0, Aerie Pharmaceuticals Inc has a PE of 0 with a one-year low of $10.82 and a 52 week high of $35.32.
A total of 7 analysts have released a research note on the stock. Three firms rate the company a strong buy, three firms rate the company a buy, 0 firms rate the company a hold, 0 rate the company to underperform, and lastly 0 brokeragesrate the company as sell with a one year target stock price of $45.71
General Company Details For Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. Its product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Rhopressa is a once-daily eye drop and a triple-action netarsudil ophthalmic solution. The active ingredient in Rhopressa acts through the inhibition of both Rho Kinase (ROCK) and norepinephrine transporter (NET). Roclatan is a once-daily, quadruple-action product candidate and is a fixed-dose combination of Rhopressa and latanoprost, and which is a prescribed drug for the treatment of patients with glaucoma. The Company is engaged in conducting Phase III clinical trials for Rhopressa and Roclatan.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.